Best Healthcare Stocks Based on Genetic Algorithms: Returns up to 21.19% in 7 Days

Best Healthcare Stocks

This Healthcare Stocks Package is designed for investors and analysts who need predictions of the best shares within the Healthcare Sector. It includes 20 stocks with bullish and bearish signals and indicates the best healthcare stocks to buy and sell:

  • Top 10 HealthCare stocks for the long position
  • Top 10 HealthCare stocks for the short position

Healthcare
Package Name: HealthCare Stocks
Recommended Positions: Long
Forecast Length: 7 Days (12/05/2017 – 12/12/2017)
I Know First Average: 3.96%
Best Healthcare Stocks

In this 7 Days forecast for the HealthCare Stocks Package, there were many high performing trades and the algorithm correctly predicted 7 out 10 trades. The top-performing prediction in this forecast was SCMP, which registered a return of 21.19%. Other notable stocks were DVA and TEVA with a return of 13.68% and 9.77%. The package had an overall average return of 3.96%, providing investors with a premium of 3.03% over the S&P 500’s return of 0.93% during the same period.

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the United States, Japan, Switzerland, and internationally. The company’s marketed product includes AMITIZA (lubiprostone), a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation in adult women (IBS-C), and opioid-induced constipation (OIC)in patients with chronic non-cancer related pain; and RESCULA (unoprostone isopropyl), a big potassium channel activator for the treatment of glaucoma and ocular hypertension. Its product candidates in clinical development stage comprise Lubiprostone that is in Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) in adults, IBS-C in adult women, and OIC in patients with chronic non-cancer pain, as well as CPP-1X/sulindac combination product, which has completed Phase III clinical trials for the treatment of familial adenomatous polyposis. The company is also developing VTS-270, which is in a pivotal Phase 2b/3 trial for the treatment of Niemann-Pick Disease Type C1. Sucampo Pharmaceuticals, Inc. was founded in 1996 is headquartered in Rockville, Maryland.

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.

How to interpret this diagram

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.